economy
Eli Lilly opposes push to pass Trump's drug pricing deals into law, CEO says
Eli Lilly opposes the White House's push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said in an interview with CNBC.
TL;DR
- Eli Lilly CEO Dave Ricks opposes the White House push to codify "most favored nation" drug pricing into law.
- The company previously signed deals with the Trump administration to align U.S. prices with those in other wealthy nations.
- Ricks fears that codifying these deals could harm future drug innovation and the U.S. pharmaceutical industry.
- Lilly has communicated its concerns to the administration and congressional leaders.
- The company is prepared to use "all the tools we have to combat bad policy" that it views as detrimental.